Financial support program for cancer clinical trial participants
Official title: Enhancement of Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program
Run by University of Texas Southwestern Medical Center · NCT05402033 · Data updated 2026-11-12
This study is testing a financial support program for people in cancer clinical trials to see if it helps more patients join and improves their experiences.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 1200 (estimated) |
| Sponsor | University of Texas Southwestern Medical Center Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Status | Recruiting |
| Started | July 12, 2022 |
| Main results expected | June 1, 2029 |
| Study ends | June 1, 2030 |
| Registry record updated | September 2, 2026 |
| Trial ID | NCT05402033 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this program are individuals currently enrolled in therapeutic cancer clinical trials who can communicate in English or Spanish.
✕Probably not a fit
Patients who are not enrolled in a clinical trial or do not speak English or Spanish will not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This program aims to implement a Financial Reimbursement and Outreach initiative at the Harold C. Simmons Comprehensive Cancer Center to assess its impact on the enrollment and demographics of participants in cancer clinical trials. The study will involve surveys and interviews to gather data on patient experiences, barriers, and facilitators related to the program. Participants will complete two surveys and may be invited for follow-up interviews to provide deeper insights into their experiences with the reimbursement program.
Why it matters
Potential benefit: If successful, this program could enhance participation in cancer clinical trials by alleviating financial burdens for patients.
How similar studies have gone: While financial reimbursement programs in clinical trials are not widely tested, similar initiatives have shown promise in improving patient recruitment and retention in other healthcare settings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Be enrolled in a therapeutic cancer clinical trial * Speak English or Spanish Exclusion Criteria: * Not enrolled in a clinical trial * Does not speak English or Spanish
Where it's running
-
University of Texas Southwestern Medical Center
Dallas, Texas, United States Recruiting
Study contacts
- Principal investigator: David E Gerber, MD — Professor
- Study coordinator: Rebecca Renn
- Email: Rebecca.Renn@utsouthwestern.edu
- Phone: 214-648-7097
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tirzepatide for methamphetamine use disorder (phase 2)
This phase 2 trial tests whether weekly tirzepatide injections can help adults with moderate to severe methamphetamine use disorder reduce use and improve outcomes compared with placebo.
-
Do beverage cues drive craving in adults with AUD
In adults with alcohol use disorder, this study tests whether different non-alcoholic beverage cues can trigger cravings differently when people see and smell them without drinking.
-
How foot braces might help people with ataxia walk better
This study tests whether wearing foot orthoses at home can improve gait and balance for adults with cerebellar ataxia.
-
Personalized Ultrafractionated Stereotactic Radiotherapy with Perioperative FLOT for GEJ and Esophageal Cancer
This trial tests adding a personalized, ultra-fractionated radiotherapy boost (PULSAR) to standard perioperative FLOT chemotherapy for patients with esophageal or gastroesophageal junction cancer to see if it can be used safely.
-
Hemophilia A: comparing long-acting FVIII replacement vs non-FVIII therapy in kids
This study tests whether children with moderate to severe Hemophilia A on long-acting FVIII or non-FVIII therapies form clots differently and develop small joint bleeds or early joint changes.
-
Adaptive dosing of immune therapy for hepatocellular carcinoma
This trial tests whether changing the dosing schedule of nivolumab plus ipilimumab can help people with hepatocellular carcinoma who have Child-Pugh B liver disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.